Abstract:Arsenic plus all-trans retinoic acid (ATRA) as front-line treatment for acute promyelocytic leukaemia (APL) achieves a cure rate of over 90%.1 However, some patients still experience relapse due to arsenic resistance with or without PML mutations.2, 3 Patients with arsenic resistance have also been shown to be resistant to ATRA and conventional chemotherapies, and their survival outcomes were very poor.3 Novel drugs to overcome arsenic resistance are urgently needed. Venetoclax, a bcl2 inhibitor, has become a front-line treatment for elderly acute myeloid leukaemia (AML) patients,4 and it can suppress oxidative phosphorylation and selectively target leukaemic stem cells. High bcl2 expression and oxidative phosphorylation dependence of APL cells render venetoclax a promising candidate. In vitro, NB4 or primary APL cells were more sensitive to venetoclax than non-APL cells.5 Moreover, we found that PML-A216V/T-mutated APL cells from arsenic-resistant patients exhibited high sensitivity to venetoclax and high resistance to ATRA, arsenic trioxide and daunorubicin (Figure 1D). Venetoclax could induce apoptosis of PML-mutated APL cells at a clinically feasible concentration (1–5 μM). Clinically, we empirically found that a priming regimen of CAG (cytarabine, aclarubin and granulocyte colony-stimulating factor) could eliminate minimal residual disease in APL patients. Therefore, we performed a pilot study to evaluate the venetoclax plus CAG regimen (V-CAG) for the treatment of arsenic-resistant relapsed and refractory APL. The study was approved by the Institutional Review Board of the First Affiliated Hospital, Zhejiang University School of Medicine (No.960) and was conducted in accordance with the principles of the Declaration of Helsinki. From January 2020 to May 2021, nine patients were enrolled. The V-CAG regimen is shown in Figure 1A. The median age of the patients was 35 years, and the number of relapses is three (range 1–6). All patients were resistant to arsenic prior to receiving the V-CAG treatment. Eight patients achieved complete remission (CR), among whom three achieved complete molecular remission (CMR), and one achieved partial remission (PR) (Figure 1B). The haematological toxicities were mild (Figure 1C). Three patients had infections (grade 2–3), and no tumour lysis syndrome occurred during V-CAG treatment. One to two cycles of the V-CAG regimen was used as a post-remission treatment. Two patients received allo-HSCT, and the others received venetoclax as one month on and one month off cycles as maintenance therapy. As of 20 July 2021, nine patients were alive (eight in continuous CR, one in PR). Here, we demonstrated for the first time that venetoclax-based treatment can overcome arsenic resistance in APL patients with a high CR rate and potential survival advantage. We previously reported that 11 out 13 arsenic-resistant APL patients died rapidly when treated with conventional chemotherapy.2 However, in this study, all nine arsenic-resistant patients achieved CR/PR and were still alive after receiving venetoclax-based treatment. Moreover, the V-CAG regimen showed good safety with mild marrow suppression, and no tumour lysis syndromes or deaths occurred. A larger sample size and longer follow-up period are warranted. This work was supported by grants from the Leading Innovative and Entrepreneur Team Introduction Programme of Zhejiang (2020R01006 and 2019R01001 to Hong-Hu Zhu). The authors declare no competing financial interests. Hong-Hu Zhu, Hua Naranmandura and Jie Jin had full access to all of the data and take responsibility for the data integrity and analysis; Qian Qian Wang, Hua-Feng Wang and Jian-Zhi Zhao contributed to the molecular analysis and data collection, and all authors contributed to the final draft.

A Case of Relapsed/Refractory CD56-Positive Acute Promyelocytic Leukemia, in Which Complete Molecular Remission Was Achieved Following Combination Therapy with Venetoclax and Azacitidine

First Case of Acute Promyelocytic Leukemia with TFG-RARA Achieved Complete Remission Treated with Venetoclax and All-Trans Retinoic Acid

Long-Term Efficacy of Low-Dose All-Trans Retinoic Acid Plus Individually Adapted Chemotherapy Induction Followed by Arsenic Trioxide Based Post-Remission Therapy in Adults with Newly Diagnosed Acute Promyelocytic Leukemia

Venetoclax Plus Cytarabine and Azacitidine in Relapsed/Refractory AML: an Open-Label, Single-arm, Phase 2 Study.

15-Days Duration of Venetoclax Combined with Azacitidine in the Treatment of Relapsed/Refractory High-Risk Myelodysplastic Syndromes: A Retrospective Single-Center Study

Long-Term Efficacy Of Low-Dose All-Trans Retinoic Acid Plus Minimal Chemotherapy Induction Followed By The Addition Of Intravenous Arsenic Trioxide Post-Remission Therapy In Newly Diagnosed Acute Promyelocytic Leukaemia

Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report

[Refractory acute promyelocytic leukemia with a complex karyotype]

Venetoclax Plus “3+7” Chemotherapy As the First-Line Therapy for Adult Patients with Acute Myeloid Leukemia

Acute Promyelocytic Leukemia With Long and Short Isoforms of PML::RARA Fusion Transcripts Complicated by Abdominal Distension and Acute Edematous Pancreatitis During Induction Treatment: A Case Report

Successfully treatment of PLZF-RARα positive acute promyelocytic leukemia by Venetoclax combining with decitabine: a case report and literature review

Efficacy and Safety of Venetoclax in Combination with Cytarabine and Azacitidine (VAA) in Relapsed/refractory Acute Myeloid Leukemia: an Open-Label, Single-Arm, Phase II Study.

Venetoclax for Arsenic-Resistant Acute Promyelocytic Leukaemia

Treatment of STAT5b-RARA Positive Acute Promyelocytic Leukemia by Venetoclax Combining with Homoharringtonine, Cytarabine: A Case Report and Literature Review

Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature

Venetoclax for an ATRA and ATO resistance acute promyelocytic leukemia patient with TNRC18::RARA fusion gene

Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia

Case Report: Very Late, Atypical Extra-Medullary Relapse in a Patient With Acute Promyelocytic Leukemia (APL) Rescued With a Transplant-Free Approach

A case report of atypical chronic myeloid leukemia with complete hematological and major molecular response to Venetoclax/Azacitidine treatment

Preliminary Results of a Consolidation Therapy Consisting Single Anthracycline Agent and Alternative All-Trans Retinoic Acid in Acute Promyelocytic Leukemia

Case Report: Successful Therapy with All-Trans Retinoic Acid Combined with Chemotherapy Followed by Hematopoietic Stem Cell Transplantation for Acute Promyelocytic Leukemia Carrying the BCOR-RARA Fusion Gene